• Jiaying Li, Li Li, Gulijiang Mahesutihan, Juanjuan Meng, Yuan Chen, and Jingsen Lv.
• Department of Pharmacy, Branch of the First Affiliated Hospital of Xinjiang Medical University, Changji, Xinjiang, China.
• Medicine (Baltimore). 2023 Mar 3; 102 (9): e32972e32972.

BackgroundBreast invasive cancer (BRCA) is the most common malignancy and the second leading cause of malignancy death among women. Signal transducers and activators of transcription (STAT) family played a vital role in regulating certain biological processes and could serve as biomarkers for many diseases or cancers.MethodsThe expression, prognostic value, and clinical functions of STAT family in BRCA were evaluated with several bioinformatics web portals.ResultsThe expression of STAT5A/5B were downregulated in BRCA in subgroup analyses based on race, age, gender, race, subclasses, tumor histology, menopause status, nodal metastasis status, and TP53 mutation. BRCA patients with high STAT5B expression had a better overall survival, relapse free survival, MDFS and post progression survival. STAT5B expression level can impact the prognosis in BRCA patients with positive PR status, negative Her2 status and wild type TP53. Moreover, STAT5B was positively correlated with immune cell infiltration and the level of immune biomarkers. Drug sensitivity revealed that low STAT5B expression was resistant to the many small molecules or drugs. Functional enrichment analysis revealed that STAT5B was involved in adaptive immune response, translational initiation, JAK-STAT signaling pathway, Ribosome, NF-kappa B signaling pathway and Cell adhesion molecules.ConclusionsSTAT5B was a biomarker associated with prognosis and immune infiltration in breast cancer.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…